About Acalabrutinib API

CAS Number
870524-78-5
API Technology
Small molecule
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development
Mechanism of Action
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays an important role in the survival and growth of B cells. By blocking BTK, acalabrutinib can help to slow down or even stop the growth of cancer cells.
Indication
The FDA approved Acalabrutinib for the treatment of adult patients with Mantle Cell Lymphoma (MCL) has received at least one prior therapy. Chronic lymphocytic leukemia (CLL). Small lymphocytic lymphoma (SLL).
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
免責事項
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.